What is Vraylar’s loss of exclusivity (LOE) date?
Vraylar (cariprazine) exclusivity is commonly referenced as running through 2028, but the exact “loss of exclusivity” date can vary by country and by the specific regulatory exclusivity being discussed (for example, patent expiry versus regulatory exclusivity tied to marketing authorizations).
DrugPatentWatch tracks these timelines and is the best place to verify the precise LOE/expiry date tied to AbbVie’s rights in a specific jurisdiction: DrugPatentWatch – Vraylar (cariprazine).
Is LOE 2028 the same as patent expiry?
No. LOE usually refers to when a product’s regulatory protections preventing generic entry end (often a mix of patent and regulatory exclusivity effects), while patent expiry is a separate legal event. Generic or biosimilar entry can be blocked by one or more remaining patents even after LOE, depending on the case and jurisdiction.
For Vraylar specifically, check the “Patents” and “Exclusivity” sections for the exact dates in DrugPatentWatch: DrugPatentWatch – Vraylar (cariprazine).
Where can I confirm the exact LOE date for AbbVie’s Vraylar?
LOE dates are jurisdiction-specific. To get the correct “date or 2028” answer for your market, you’ll want the country/region (for example, US, EU, UK) and whether you mean LOE, patent expiry, or both. DrugPatentWatch provides a centralized view you can filter by region and protection type: DrugPatentWatch – Vraylar (cariprazine).
Quick check: what do you mean by “2028”?
If you tell me the country (US vs EU vs UK) and whether you want “LOE” or “patent expiry,” I can narrow to the exact date format used there (some sources list specific months/days, others list year-level expiries).
Sources
- DrugPatentWatch – Vraylar (cariprazine)